148 related articles for article (PubMed ID: 1383735)
1. Cell cycle effects of the DNA topoisomerase inhibitors camptothecin and m-AMSA in lymphoblastoid cell lines from patients with Fanconi anemia.
Poot M; Epe B; Hoehn H
Mutat Res; 1992 Nov; 270(2):185-9. PubMed ID: 1383735
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerases and the DNA lesion in human genetic instability syndromes.
Poot M; Hoehn H
Toxicol Lett; 1993 Apr; 67(1-3):297-308. PubMed ID: 8383888
[TBL] [Abstract][Full Text] [Related]
3. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity.
Poot M; Hiller KH; Heimpel S; Hoehn H
Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696
[TBL] [Abstract][Full Text] [Related]
4. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
5. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
6. Impaired S-phase transit of Werner syndrome cells expressed in lymphoblastoid cell lines.
Poot M; Hoehn H; Rünger TM; Martin GM
Exp Cell Res; 1992 Oct; 202(2):267-73. PubMed ID: 1327851
[TBL] [Abstract][Full Text] [Related]
7. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Jones NJ; Ellard S; Waters R; Parry EM
Carcinogenesis; 1993 Dec; 14(12):2487-94. PubMed ID: 8269616
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
9. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro.
Backer LC; Allen JW; Harrington-Brock K; Campbell JA; DeMarini DM; Doerr CL; Howard DR; Kligerman AD; Moore MM
Mutagenesis; 1990 Nov; 5(6):541-7. PubMed ID: 2175833
[TBL] [Abstract][Full Text] [Related]
10. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Ellis AL; Nowak B; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle defect in connection with oxygen and iron sensitivity in Fanconi anemia lymphoblastoid cells.
Poot M; Gross O; Epe B; Pflaum M; Hoehn H
Exp Cell Res; 1996 Feb; 222(2):262-8. PubMed ID: 8598212
[TBL] [Abstract][Full Text] [Related]
12. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F
Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937
[TBL] [Abstract][Full Text] [Related]
13. Werner's syndrome lymphoblastoid cells are hypersensitive to topoisomerase II inhibitors in the G2 phase of the cell cycle.
Pichierri P; Franchitto A; Mosesso P; Proietti de Santis L; Balajee AS; Palitti F
Mutat Res; 2000 Mar; 459(2):123-33. PubMed ID: 10725663
[TBL] [Abstract][Full Text] [Related]
14. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
Lefevre D; Riou JF; Ahomadegbe JC; Zhou DY; Benard J; Riou G
Biochem Pharmacol; 1991 Jun; 41(12):1967-79. PubMed ID: 1645555
[TBL] [Abstract][Full Text] [Related]
15. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
16. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
17. Fanconi anemia cells have a normal gene structure for topoisomerase I.
Saito H; Grompe M; Neeley TL; Jakobs PM; Moses RE
Hum Genet; 1994 May; 93(5):583-6. PubMed ID: 8168839
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of DNA topoisomerase inhibitors on lymphoblasts from normal and Fanconi anemia donors.
Rosselli F; Duchaud E; Averbeck D; Moustacchi E
Mutat Res; 1994 Dec; 325(4):137-44. PubMed ID: 7527905
[TBL] [Abstract][Full Text] [Related]
19. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells.
Del Bino G; Skierski JS; Darzynkiewicz Z
Exp Cell Res; 1991 Aug; 195(2):485-91. PubMed ID: 1649059
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic effects of inhibition of topoisomerase I or II activities in the CHO mutant EM9 and its parental line AA8.
Cortés F; Piñero J; Palitti F
Mutat Res; 1993 Aug; 288(2):281-9. PubMed ID: 7688089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
